afamitresgene autoleucel

FDA Drug Profile — TECELRA

afamitresgene autoleucel is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including TECELRA. Available dosage form: injection, suspension.

Drug details

Generic Name
afamitresgene autoleucel
Brand Names
TECELRA
Application Number
BLA125789
Sponsor
USWM, LLC
NDC Codes
4
Dosage Forms
INJECTION, SUSPENSION
Routes
INTRAVENOUS
Active Ingredients
AFAMITRESGENE AUTOLEUCEL

Indications and Usage

1 INDICATIONS AND USAGE TECELRA is indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.